Rhizome AI Reviews

Rhizome AI Description

Rhizome serves as an AI regulatory collaborator specifically designed for teams in the life sciences sector. While general AI assistants offer remarkable capabilities, there are distinct requirements for an AI tool that aids in making decisions regarding drugs or devices worth over $100 million.

Our agents are strictly limited to referencing facts derived from primary source documents, ensuring that nothing is validated based on agent memory; we assess their performance based on this criterion, and there have been no instances of inaccuracies reported in the past 18 months.

The databases that underpin regulatory decisions, including Drugs@FDA, guidance documents, clinicaltrials.gov, and various standards, often exist in formats that are not easily searchable by computers, with a significant amount being image-only PDFs. We have developed the ability to ingest and process all of this information, encompassing over 75 health authority databases across more than 12 markets as of August 2026, with this number continually growing. This equates to over 45 million documents that our agents can query comprehensively.

In contrast to a general assistant, which typically references 5 to 10 sources, Rhizome is capable of examining hundreds to thousands of documents, as the essential question is often, "Did we overlook a precedent?" This thorough approach ensures that our users are equipped with the most comprehensive and accurate information possible.